Dialpad Raises $170 Million and Increases Valuation to $2.2 Billion as it Leads New Era of AI-Powered Communications
Dialpad Inc., the industry leader in AI-powered cloud communications and collaboration, today announced $170 million in funding. The amount raised and valuation of $2.2 billion reflects the increasing importance of a truly unified approach to business communications. To date, Dialpad has raised $418 million in capital.
ICONIQ Capital leads the funding round which includes participation from Amasia, GV, OMERS Growth Equity, Work-Bench, Section 32, and T-Mobile Ventures. Dialpad will use this funding to invest in the further development and application of native artificial intelligence (AI) throughout its unified platform; hiring top talent across data engineering, natural language processing, machine learning and customer-facing roles to support its rapid global growth.
“Dialpad is the world’s most advanced AI-powered communications, collaboration, and contact center platform, providing a customer- and cloud-first solution that enables more efficient and effective conversations,” said Craig Walker, founder and CEO, Dialpad. “This latest round of funding, and increased valuation, showcases Dialpad’s continued momentum and strengthens our dedication to helping companies scale and enterprises thrive in today’s hybrid, work-from-anywhere world.”
“Dialpad is at the forefront of cloud-based, native AI communications, collaboration, and contact center solutions. ICONIQ Capital is proud to again invest in Dialpad’s vision to deliver streamlined communications combined with crucial data-driven insights all through one application,” said Will Griffith, Founding Partner, ICONIQ Capital. “As the creator of Google Voice, Craig Walker knows what it means to disrupt an entire category. Walker recognized the pain points consumers had communicating at scale in the cloud. Now, he is applying that same philosophy with Dialpad, extending it to the enterprise and is once again disrupting the status quo.”
Dialpad is the one place for truly unified Communications as a Service (TrueCaaS™), offering companies and employees the ability to work smarter — not harder — from anywhere on any device. In today’s distributed world, teams need one seamless solution for productive collaboration that also avoids the growing phenomenon of “app overload”. Simple to deploy and backed up with Voice Intelligence (Vi™) to create a searchable archive of every call, Dialpad delivers all modes of business communications through a single pane of glass.
“Customer adoption of Dialpad’s AI-powered TrueCaaS platform is at an all time high and is accelerating,” said Mike Kourey, Chief Financial Officer, Dialpad. “This $170 million financing round further fuels our unparalleled innovation engine and global expansion, advancing Dialpad’s comprehensive vision for the future of work, business communications and collaboration, and customer experience.”
The funding round is the latest development in a year of significant milestones for Dialpad including growth, global expansion, partnerships and acquisitions.
- C-suite expansion to include chief officers for finance, marketing and human resources, technology and operations
- 50% headcount increase year-over-year to nearly 1,000 employees with expanded operations into Australia, New Zealand, Japan, and EMEA
- Acquisitions of Kare Knowledgeware and Koopid to elevate the customer and agent experience with digital self-service, conversational AI, and intelligent omnichannel support
- Partnerships with T-Mobile for Business to enhance work-from-anywhere collaboration
- More than two billion minutes of data analyzed establishing Dialpad Vi transcription model as most accurate in business communications industry
- Recognized as a Major Player in the 2021 IDC MarketScape, included in the Gartner Magic Quadrant for third consecutive year, the 2021 Contact Center Buyers Guide from Frost & Sullivan, and named a leader in the 2021 SPARK Matrix and multiple G2 categories
- Multi-year jersey patch sponsorship and official communications provider with the Sacramento Kings of the NBA which includes notable philanthropic initiatives
Additional Resources
- Read more about Dialpad’s acquisitions of Kare and Koopid
- Learn how Dialpad’s growing partner ecosystem is improving customer experiences
- For more information on Dialpad’s recent CFO appointment, see the press release
Social Networks:
- Web: https://www.dialpad.com/
- Blog: https://www.dialpad.com/blog/
- Twitter: https://twitter.com/dialpadHQ/
- LinkedIn: https://www.linkedin.com/company/dialpad/
- Facebook: https://www.facebook.com/DialpadHQ/
- Instagram: https://www.instagram.com/DialpadHQ/
About Dialpad
Dialpad is the global leader in AI communications for business, transforming how the world works together. Dialpad customers benefit from truly unified business and customer communications, including a cloud business phone system, text and team messaging, video meetings, and the world’s most advanced AI-powered contact center — all in one beautiful app. More than 7,000 innovative brands and millions of people use Dialpad to connect their teams from anywhere including Motorola Solutions, Netflix, T-Mobile, Uber and WeWork. Visit www.dialpad.com for more information and to request a demo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005248/en/
Contact information
Gavin Gustafson
gavin@dialpad.com
801-255-9915
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
